Abstract
Summary
1. This is an early evaluation of a new, non-sulfonylurea hypoglycemic agent. 2. In this study of 20 cases, DBI, the hydrochloride of N1beta-phenethylformamidinylimino urea, appears to have definite blood sugar lowering properties. The mechanism of action is not yet known. 3. There are annoying side effects in some cases which are restricted to the gastrointestinal tract and are not related to the blood sugar levels. 4. No other annoying or toxic effects have been observed at this time. 5. The size of the effective blood sugar lowering dose is smaller than that reported for other oral hypoglycemic agents.
Get full access to this article
View all access options for this article.